SEC Form 4 · accession 0001816160-26-000009
ACADIA PHARMACEUTICALS INC · ACAD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Kihara
Officer — PRINCIPAL ACCOUNTING OFFICER
Period of report
Jun 26, 2026
Accepted (ET)
Jun 29, 2026 · 6:00 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001070494
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 26, 2026 | S | 11,421 | $26.0846 | D | 13,088 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 9, 2025.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.88 to $26.265, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.